Pfizer Ltd. — Regulatory Filings 2021

May 26, 2021

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 26, 2021

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Audited financial results and Audit Report for the financial year ended March 31, 2021

Pursuant to Regulation 33 of the SEBI (Listing Obligation Disclosure Requirements) Regulations, 2015, we submit herewith audited financial results for the financial year ended March 31, 2021, Statement of Assets and Liabilities as on March 31, 2021, Statement of Audited Cash Flows for the year ended March 31, 2021, Declaration with respect to Audit Report with unmodified opinion and the Auditor's Report by Auditors, M/s. Walker Chandiok & Co LLP, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.15 p.m. and concluded at 4.00 p.m.

Further, please be informed that the Board of Directors of the Company has recommended a normal dividend of Rs. 30/- per equity share of Rs. 10/- each (300%) and a special dividend of Rs. 5/- per equity share of Rs. 10/- each (50%), aggregating to total dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the year ended March 31, 2021. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 15, 2021.

We request you to kindly take the same on record.

Thanking you,

Yours truly, For Pfizer Limited

Prajeet Nair Company Secretary

Encl: A/a

Cc: National Securities Depository Limited (NSDL) Central Depository Services (India) Limited (CDSL) Kfin Technologies Private Limited

Walker Chandiok &.Co LLP

Wiiker Ch1ndlok & Co LLP 21"' Floor, DLF Square Jacaranda Marg, DLF Phase II Gurugram - 122 002 Inch a

T +91 124 4628099 F +91 124 4628001

Independent Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Pfizer Limited

Opinion

• 1. We have audited the accompanying annual financial results ('the Statement') of Pfizer Limited ('the Company') for the year ended 31 March 2021 , attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('listing Regulations'), including relevant circulars issued by the SEBI from time to time.
• 1. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
• (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
• (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2021 .

Basis for Opinion

3 We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143( 10) of the Act. Our responsibilities under those standards are further described tn the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

(This space has been intentionally left blank)

Cha11nc1Accollntantl

Of!icea in Be"91furu Clllndlp!I Chennai. Gurup!\ HyooraolG ~oc'11. ~ala. M.lmOll. ,._ Delh. Nolda n Pune

W.lkw Chandiok & Co LLP it rwg.at•ed w ith llln~ed loebdrty wit"I l~1cebon nunber MC-2085 end U reg.stered o!!ice et L -<11 ConNught Circus. New Otlhl. 110001 India

Walker Chandiok &.Co LLP

Responsibilities of Management and Those Charged with Governance for the Statement

• 1. This Statement has been prepared on the basis of annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
• 1. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so
• 1. The Board of Directors is also responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Statement

• 1. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
• 1. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
• Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.

% (This space has been intentionally left blank) ^~

~ ~ ~'>ii' D cc~

Walker Chandiok &.Co LLP

• Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
• 1. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
• 1. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11 . The Statement includes the financial results for the quarter ended 31 March 2021 , being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No.: 00

shish Gupta Partner

Membership No. 504662

UDIN: 21504662AAAADP9206

Place: New Delhi Date: 26 May 2021

Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

Statement of Audited Financial Results for the Quarter and Year ended 31 March, 2021

					( ` in crore except earning per share)
	3 months ended 31/03/2021	Preceding 3 months ended 31/12/2020	Corresponding 3 months ended in the previous year 31/03/2020	Year to date figures for current year ended 31/03/2021	Year to date figures for previous year ended 31/03/2020
Particulars	Audited	Unaudited	Audited	Audited	Audited
1 Income
(a) Revenue from operations	534.76	593.49	502.01	2,238.55	2,151.65
(b) Other income	37.20	14.57	45.22	81.12	184.02
Total income	571.96	608.06	547.23	2,319.67	2,335.67
2 Expenses
(a) Cost of materials consumed	87.37	91.04	90.22	334.74	345.21
(b) Purchases of stock-in-trade	43.15	183.42	198.28	448.65	483.81
(c) Changes in inventory of finished goods, work-in-progress and
stock-in-trade	65.25	(61.89)	(97.35)	14.35	(36.62)
(d) Employee benefits expense	94.83	94.12	100.65	361.06	364.51
(e) Finance costs	3.54	3.85	3.62	15.11	10.85
(f) Depreciation and amortization expense	27.31	27.23	28.41	109.41	103.24
(g) Other expenses	118.42	90.03	101.50	367.63	422.18
Total expenses	439.87	427.80	425.33	1,650.95	1,693.18
3 Profit before tax (1 - 2)	132.09	180.26	121.90	668.72	642.49
4 Tax expense
(a) Current tax	39.07	37.91	32.43	183.63	177.70
(b) Deferred tax	(7.53)	1.11	30.96	(12.52)	0.16
(c) Prior year tax reversal	-	-	(44.50)	-	(44.50)
5 Net profit for the period / year (3 - 4)	100.55	141.24	103.01	497.61	509.13
6 Other comprehensive income
(a) Items that will not be reclassified subsequently to profit or loss	7.53	(2.94)	(6.94)	(1.28)	(11.94)
(b) Income tax related to items that will not be reclassified to profit or loss	(1.90)	0.74	1.75	0.32	3.01
Other comprehensive income, net of taxes	5.63	(2.20)	(5.19)	(0.96)	(8.93)
7 Total comprehensive income for the period / year (5 + 6)	106.18	139.04	97.82	496.65	500.20
8 Paid-up equity share capital (Face value per share `10)	45.75	45.75	45.75	45.75	45.75
9 Other equity				2,347.29	3,349.74
10 Earnings per share - Basic and Diluted (of `10/- each) Computed on the basis of net profit for the period / year	21.98*	30.87*	22.52*	108.77	111.28

*Earnings per share - Basic and Diluted (of `10/- each) not annualised

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerindia.com

Balance Sheet as at 31 March, 2021

(` in crore)

	As at	As at
Particulars	31 March 2021	31 March 2020
	Audited	Audited
ASSETS
Non-current assets
Property, plant and equipment	192.38	214.52
Capital work-in-progress	2.76	0.76
Investment property	29.56	30.95
Goodwill	527.49	527.49
Other intangible assets	144.87	199.90
Financial assets
Investments *	0.00	0.00
Loans	32.31	31.90
Other non-current assets	168.53	141.69
Deferred tax assets (net)	13.46	0.62
Income tax receivable (net)	229.83	209.32
Total non-current assets	1,341.19	1,357.15
Current assets
Inventories	435.05	430.59
Financial assets
Trade receivables	129.69	172.03
Cash and cash equivalents	157.03	1,763.79
Bank Balance other than cash and cash equivalents	958.07	456.08
Loans	8.56	3.52
Other financial assets	51.97	21.31
Other current assets	149.16	165.75
Assets held for sale	35.18	35.18
Total current assets	1,924.71	3,048.25
TOTAL ASSETS	3,265.90	4,405.40
EQUITY AND LIABILITIES
Equity
Equity share capital	45.75	45.75
Other equity	2,347.29	3,349.74
Total equity	2,393.04	3,395.49
Liabilities
Non current liabilities
Financial liabilities
Other financial liabilities	42.68	88.68
Provisions	55.84	47.87
Total non-current liabilities	98.52	136.55
Current liabilities
Financial liabilities
Borrowings	2.50	2.50
Trade payables
Due to micro enterprises and small enterprises	1.33	9.33
Due to others	282.41	417.45
Other financial liabilities	134.18	118.06
Other current liabilities	227.29	222.31
Provisions	80.63	57.71
Current tax liabilities (net)	46.00	46.00
Total current liabilities	774.34	873.36
Total liabilities	872.86	1,009.91
TOTAL EQUITY AND LIABILITIES	3,265.90	4,405.40

* Amount below ` one lakh

Statement of Audited Cash Flows for the Year ended 31 March, 2021

		(` in crore)
Particulars	For the year ended 31/03/2021	For the year ended 31/03/2020
	Audited	Audited
Cash from operating activities
Profit before tax	668.72	642.49
Adjustments to reconcile profit before tax to net cash used in operating activities
Depreciation and amortization expenses	109.41	103.24
Interest on deposits with banks and others	(38.74)	(129.54)
Provisions no longer required written back	(4.73)	(12.74)
(Reversal)/Allowance for expected credit loss	(0.52)	2.09
Provision for doubtful loans (deposits)	0.08	0.21
(Profit)/Loss on sale/disposal of Property plant & equipment (net)	(0.08)	1.11
Unrealised foreign exchange (gain)/loss	(1.59)	0.38
Employee stock option expenses	10.56	8.04
Rental income	(6.39)	(6.39)
Interest expense	15.11	10.85
Compensation for wind down of Consumer health business (net)	(24.36)	-
Sale of rights and interest in brands (net of related expenses)	(3.25)	(30.53)
Gain on early termination of lease	(0.97)	(0.28)
Operating profit before working capital adjustments Working capital adjustments	723.25	588.93
(Increase)/Decrease in inventories	(4.46)	(43.93)
(Increase)/Decrease in trade receivables	42.86	(2.46)
(Increase)/Decrease in other current and non current assets	(32.96)	(13.15)
Increase/(Decrease) in trade payables	(140.93)	3.22
Increase/(Decrease) in current and non current liabilities	3.81	7.31
Increase/(Decrease) in provisions	39.90	(3.45)
Cash generated from operations	631.47	536.47
Income tax paid	(204.14)	(213.29)
Net cash generated from operating activities (A)	427.33	323.18
Cash from investing activities Purchase of property, plant and equipment*	(17.70)	(16.89)
Additions to asset held for sale	-	(21.50)
Proceeds from sale of property, plant and equipment	0.08	0.23
Proceeds from assignment / sale of trademarks (including transfer of inventories)	-	36.34
(Increase)/ Decrease in bank balances other than cash and cash equivalents	(501.99)	1384.27
Rent received	6.45	7.90
Interest received	44.32	139.97
Net cash used in/ generated from investing activities (B)	(468.84)	1,530.32
Cash from financing activities
Payment of Lease liablities	(49.09)	(39.00)
Interest paid	(2.63)	(0.43)
Dividend paid	(1,519.35)	(102.93)
Dividend distribution tax paid	-	(21.16)
Net cash used in financing activities (C)	(1,571.07)	(163.52)
Net (Decrease)/increase in cash and cash equivalents (A+B+C)	(1,612.58)	1,689.98
Cash and cash equivalents at the beginning of the year	1,763.79	73.81
Cash and cash equivalents at the end of the year (Refer note 1)	151.21	1,763.79
Note: 1	As at	As at
	31 March 2021	31 March 2020
Cash and cash equivalents	157.03	1,763.79
Book Overdraft	(5.82)	-
Net Cash and cash equivalents	151.21	1,763.79

*Purchase of property, plant and equipment represents additions to property, plant and equipment adjusted for movement of capital work in progress,capital advances,capital creditors and investment properties during the year.

NOTES:

• 1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on May 26, 2021 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date.
• 1. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016.
• 1. The financial results for the year ended March 31, 2021 have been audited by the statutory auditors of the Company. The audit report does not contain any modifications. The audit report will be filed with the Stock Exchanges and will also be available on the Company's website - www.pfizerindia.com
• 1. Figures for the quarter ended March 31, 2021 and March 31, 2020 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2020 and December 31, 2019 respectively which were subject to a limited review by the statutory auditors.
• 1. The Company has only one segment which is 'Pharmaceuticals'. Therefore disclosure relating to segments is not applicable and accordingly not made.
• 1. Pfizer Inc and GSK Plc entered into an agreement in 2018 to merge their consumer healthcare businesses into a single joint venture to form GSK Consumer Healthcare (GSKCH). This consists 2 brands - Anacin and Anne French. Subsequent to GSKCH's deliberations on the Pfizer Consumer Health (PCH) India business, Pfizer Limited has been requested to take appropriate steps to wind down the PCH business in India. Consequently, the Company will be reimbursed actual wind down cost and a compensation based on the fair value of PCH Products as determined by the independent valuers.

During the quarter the Company completed the wind down activities for its Consumer health business. The compensation of 27.5 crore derived based on the fair value of PCH Products as determined by the independent valuers, net of intangibles write off 3.1 crore is included in 'Other Income'. The aforementioned compensation along with the wind down cost of ` 11.6 crore that would be reimbursed is carried forward in the Balance Sheet as "Other Current Assets".

1. The Covid-19 pandemic has developed rapidly in 2020, with a significant number of cases globally. The Company continued with the Work From Home model and several measures were put in place for communications, technology and productivity improvements to help employees cope with this change. The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of and for the year ended March 31, 2021.

2. 1. The Board of Directors has recommended a normal dividend of ₹ 30 per equity share of ₹ 10 each (300 %) and a special dividend of ₹ 5 per equity share of ₹ 10 each (50 %), aggregating to total dividend of 35 per equity share of 10 each (350 %) for the year ended March 31, 2021.
3. 1. Figures for previous quarters / year have been regrouped / restated where necessary.

For Pfizer Limited

S. Sridhar May 26, 2021 Managing Director

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 26, 2021

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Declaration with respect to Audit report with unmodified opinion to the Audited Financial Results for the financial year ended 31st March 2021

We hereby declare that Audited Financial Results for the financial year ended March 31, 2021, which have been approved by the Board of Directors of the Company at their meeting held today, i.e. May 26, 2021, the Statutory Auditors have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made in pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Pfizer Limited

S. Sridhar Managing Director (Chief Executive Officer)